The proportion of CRC patients with MYC amplification was similar between our study and the data reported in TCGA COAD and READ datasets, while the number of patients carrying an amplification of the same gene was higher for other type of cancer (such as ovarian cancer, 41%; breast cancer, 21.2%; small cell lung cancer, 10.38%; Figure S2A). This evidence concerns the gene MYC and ovarian cancer.